Clinical Research Associates, L.L.C., an affiliate of the Simons Foundation, has recently launched a randomized controlled trial to test the safety, tolerability and efficacy of arbaclofen in 16p11.2 BP4-BP5 deletion syndrome.
Simon Chen and colleagues found that a reduction in locus-coeruleus noradrenaline neuromodulatory signaling contributes to altered motor learning in 16p11.2 deletion mice.
The International Society for Autism Research (INSAR) Virtual 2021 Annual Meeting was held May 3–7, 2021. A selection of presentations by SFARI Investigators, SFARI staff and collaborators are highlighted here. Virtual content is available online until early June 2021 (for registered meeting participants only).
Because of the coronavirus pandemic, SFARI ran the fall 2020 science meeting virtually in a series of six weekly webinars, beginning on October 2, 2020. SFARI investigators presented their latest findings in autism research, ranging from autism genetics, through molecular mechanisms and neural circuits, to clinical insights.
SFARI Investigator Aakanksha Singhvi discusses her lab’s work and how the Bridge to Independence Award helped in her transition to working as an assistant professor.
SFARI is pleased to announce that eight Director Awards were awarded in 2020. These projects include, but are not limited to, studies that aim to enhance existing SFARI-sponsored cohorts and collections, generate novel resources (e.g., animal models) and studies whose goals are beyond the focus of existing SFARI request for applications.
Gerald Crabtree, Joseph Gleeson and colleagues defined a new recessive form of ASD caused by mutations in ACTL6B, part of the BAF complex, which regulates activity-responsive transcription in resting neurons.
Peter Kind and Loren Frank discuss their work using SFARI’s genetic rat models and their views on how these models will aid autism research.
On June 22, 2019, families of people with DYRK1A syndrome gathered in Seattle to support one another and meet with researchers. A rare condition resulting from mutations to the kinase-encoding gene DYRK1A, the syndrome is associated with anomalous brain development and a range of symptoms, including microcephaly, seizures, speech delay and autism.
SFARI held its fourteenth science meeting September 30–October 2, 2018. SFARI investigators, collaborators and foundation staff came together to discuss recent findings in autism genetics, molecular and system-level mechanisms, as well as clinical studies. The meeting featured keynote and session presentations, in addition to demo sessions of online platforms for visualizing and analyzing data sets relevant for autism research.
- Previous Page
- Viewing
- Next Page